NeuroSense Reviews 2023 Achievements; Provides Road Map For 2024
NeuroSense Reviews 2023 Achievements; Provides Road Map For 2024
NeuroSense 评测 2023 年成就；提供 2024 年路线图
End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership discussions
随着公司推进合作讨论，预计与美国食品药品管理局和欧洲药品管理局的第二阶段会议将在2024年第二季度结束，预计最早将在2024年第一季度完成多项生物标志物研究结果
Statistically Significant Reduction in ALS Disease Progression in Phase 2b PARADIGM Trial
在2b期PARADIGM试验中，ALS疾病进展的统计学显著降低
Top-line results in the Phase 2b PARADIGM trial of PrimeC revealed a statistically significant slowing of disease progression in ALS patients, compared to placebo. The study demonstrated a 37.4% (p=0.03) difference in the FDA-approved ALS functional rating scale revised (ALSFRS-R), compared to placebo, and a strong safety profile. These data highlight a novel approach to treating ALS, with potential implications in other...
PrimeC的2b期PARADIGM试验的主要结果显示，与安慰剂相比，肌萎缩性侧索硬化症患者的疾病进展在统计学上显著放缓。该研...
登录免费看全文
登录/注册